A Streamlined Integrated Process to Predict Genetic Risk of Alzheimer’s Disease

Paula Daunt1, Greg Davidson2, Alex Gibson3, Anthony HPL1, Chueanin Ochende1, Ellysha Battle4, Valentina Escott-Price4, Gianna Leavens6, Rebecca Simms1, Julie Williams7, John Hardy6, Maryam Shoai6, Zsuzsanna Nagy7 and Richard Pither3

Background

The development of diagnostic tools to identify disease risk is critical to enable selection of suitable individuals for inclusion into clinical trials and cohort studies. The utility of Polygenic Risk Scores (PRS) is gaining increasing attention for generating an individual genetic risk profile and subsequent estimation of future disease risk in Alzheimer’s Disease. Cytox continues to work on the implementation of its proprietary platform, SNPfitR™ as part of a streamlined integrated process, taking DNA from either a blood or saliva sample, through genotyping and PRS calculation to produce an estimation of risk of Alzheimer’s Disease.

Acknowledgements: We would like to thank all patients that have contributed samples used in this research, our colleagues at AKESOgen, Eurofins, Ramaciotti Centre and Thermo Fisher Scientific and Innovate UK, the UK’s innovation agency who co-fund this research.

The Cytox integrated process, combining the use of a proprietary array and the SNPfitR™ software package, offers a simple and high-quality route from sample collection to AD risk assessment. This could provide an efficient, cost-effective methodology for subject enrichment in clinical trials and reduce reliance upon expensive PET imaging or invasive CSF measurement procedures.

Visit us at Booth 202 in the Exhibit Hall
www.cytoxgroup.com